Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

Running, not enrolling · Not applicable

Conditions studied: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer

In brief

The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid organs, and head and neck. This is an exploratory study designed to generate hypotheses for further research.

Key facts

Study ID

NCT00579514

Run by

Memorial Sloan Kettering Cancer Center

People needed

21081

Starts

2000-03-01

Expected to finish

2027-03-01

Last updated by the study team

2026-04-07

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a histologic diagnosis of cancer of the colon, breast, bladder, kidney, testicles, lungs, prostate, head and neck, or lymphoid organs, who have donated a diagnostic blood sample as either an inpatient or outpatient at MSKCC.
• All patients who have two or more histologic diagnoses of the same primary tumor type involving the above sites.
• Patients of Ashkenazi Jewish ancestry with a histologic diagnosis of cancer of any type.
• Samples ascertained as part of protocol 98-024A(1) are also eligible for ascertainment in this study.

You may not qualify if…

• MSKCC patients without a histologic diagnosis of cancer of the breast, bladder, kidney, colon, testicles, lungs, prostate, or lymphoid malignancy (including all types of lymphoma) will not be eligible for the AMDeC sponsored component of the study.

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.